• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

DNAzymes Dz13 target the c-jun possess antiviral activity against influenza A viruses

tetano

Editor, Senior Moderator
Microb Pathog. 2016 Dec 27. pii: S0882-4010(16)30509-5. doi: 10.1016/j.micpath.2016.12.024. [Epub ahead of print]
[h=1]DNAzymes Dz13 target the c-jun possess antiviral activity against influenza A viruses.[/h] Zhang Z[SUP]1[/SUP], Zhang S[SUP]2[/SUP], Wang S[SUP]3[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The emergence of traditional anti-influenza A virus drug resistant strains highlights the need for more effective component. The earlier study demonstrated that c-jun which is a downstream molecule of JNK appears to have an important role in virus infections and inflammatory response. In the present study we explored the function of DNAzymes Dz13 that target the c-jun in the influenza A virus infected mice model. It was demonstrated that the BALB/c mice results in no toxic side effects after Dz13 treatment. And the infected mice displayed an enhanced survival after the Dz13 treatment compared to untreated mice. Simultaneously, the pulmonary inflammatory response and viral burden also decreased in the Dz13 treated mice. Furthermore, the proliferation of CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T cells induced by virus infection was also impaired. The present data demonstrates an antiviral effect of Dz13 in vivo and the ability to reduce influenza virus induced inflammation, which suggest that Dz13 may be a potential therapeutic for influenza A virus infection.
Copyright ? 2016. Published by Elsevier Ltd.


[h=4]KEYWORDS:[/h] Antiviral; C-jun; Dz13; Influenza A virus

PMID: 28039102 DOI: 10.1016/j.micpath.2016.12.024
[PubMed - as supplied by publisher]
 
Back
Top Bottom